Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended June 30, 2012, and the 12-month period ending on that date. The company is an Australian entity admitted to the ASX on the basis of commitments, operating in the biotechnology sector.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year to Date ($A'000) |
|---|---|---|
| Receipts from Customers | 0 | 0 |
| Net Operating Cash Flows | (1,051) | (6,906) |
| Net Investing Cash Flows | (23) | (23) |
| Net Financing Cash Flows | 126 | 3,665 |
| Net Decrease in Cash | (948) | (3,264) |
| Cash at End of Period | 5,637 | 5,637 |
| Proceeds from Share Issues | 129 | 3,729 |
| Grants/Donations Received | 736 | 841 |
Debt and Liquidity: The filing indicates no borrowings, repayments, or available loan facilities. The company relies on cash reserves and equity financing. Cash on hand and at bank totaled $5,637,000 at the end of the quarter.
Material Changes and Operational Activity
- Revenue: The company reported zero receipts from customers for both the current quarter and the year-to-date period, consistent with a pre-revenue biotechnology entity.
- Burn Rate: Operating cash outflows were driven primarily by research and development ($985,000 for the quarter; $4,291,000 YTD) and staff costs ($346,000 for the quarter; $1,673,000 YTD).
- Financing: The company raised $129,000 in the quarter and $3,729,000 year-to-date through the issuance of shares and options to offset operating losses.
- Investing: Minimal investing activity occurred, with $23,000 spent on physical non-current assets for both periods.
Outlook, Risks, and Management Commentary
The filing contains no specific forward-looking guidance, management commentary on future milestones, or explicit risk factors beyond the inherent nature of the business. The primary risk indicated by the financial data is the continued negative operating cash flow and reliance on capital markets for funding. The company received $736,000 in grants/donations during the quarter, which partially offset operating costs.
Investor Verification Checklist
- Verify the company's cash runway given the quarterly burn rate of approximately $1.05 million and current cash balance of $5.6 million.
- Confirm the status of the $3.7 million in equity raised year-to-date and any dilution implications.
- Assess the progress of the $4.3 million in R&D spending against clinical or development milestones not detailed in this cash flow statement.
- Review the nature of the $841,000 in grants/donations to determine if they are recurring or one-time events.